Cogent Biosciences, Inc.

NASDAQ:COGT

Biotechnology

Healthcare
$27.74 +2.60%

+$0.88 today

Market cap
$4.83B
Beta
0.35
P/E (TTM)
-6.6
EPS (TTM)
-$5.26
52W Low $6.92High $43.73

Volume 1.68M

Average 2.15M

Returns on capital

Cogent Biosciences, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-51.7%

avg -57.6%

ROIC

-38.1%

avg -53.3%

ROA

-35.1%

avg -42.4%

Analysis

ROA is currently the strongest return metric at -35.1% versus its period average of -42.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Andrew R. Robbins

President, Chief Executive Officer & DirectorUSD 1.32M50160.00K0.09%

Jessica Sachs

Chief Medical OfficerUSD 896.62K51133.94K0.08%

John Edward Robinson

Chief Scientific OfficerUSD 868.74K52140.00K0.08%

John L. Green

Chief Financial Officer & Principal Accounting OfficerUSD 834.28K46131.83K0.08%

Cole Pinnow

Chief Commercial OfficerUSD 754.6K5165.00K0.04%

Abb Hayden

Senior Vice President of Sales————

Brad Barnett

Chief Technology Officer————

Evan D. Kearns

Chief Legal Officer & Corporate Secretary—46——

Christi Waarich

Senior Director of Investor Relations————

Erin Schellhammer

Chief People Officer————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding May 19, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

8

$383.89M

Net Transaction Value

−$383.89M

Net selling

Most Active

Morris Arlene

2 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Aug 27, 26

Morris Arlene

Direct

Sell$1.6M
Aug 27, 26

Morris Arlene

Direct

Sell$118.7K
Mar 31, 26

Fairmount Funds Management LLC

Indirect

Sell$242.6M
Jan 22, 26

Fairmount Funds Management LLC

Indirect

Sell$127.4M
Dec 26, 25

Kearns Evan

Direct

Sell$2.5M
Dec 26, 25

Green John L.

Direct

Sell$3M
Dec 26, 25

Sachs Jessica

Direct

Sell$3.2M
Dec 26, 25

Robinson John Edward

Direct

Sell$3.5M

Summary

Insiders reported 0 buys worth $0.00 and 8 sells worth $383.89M over the last 12 months. That adds up to net selling of $383.89M. Morris Arlene was the most active insider with 2 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A4 analysts
RevenueN/AN/AN/A
N/A5 analysts
Net IncomeN/AN/AN/A
N/A5 analysts
EBITN/AN/AN/A
N/A5 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Cogent Biosciences, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about COGT's management, answered from reported figures.

Who manages COGT?

Cogent Biosciences, Inc. (COGT) lists 10 active executives. The top listed executive is Jessica Sachs, Chief Medical Officer.

Are COGT insiders buying or selling?

Recent insider activity shows net selling of $229.15M.